BofA Downgrades Keryx Biopharmaceuticals (KERX) to Neutral
More News related to KERX
- Keryx Biopharmaceuticals Receives Nasdaq Notification
- Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2008 Financial Results
- Keryx Biopharmaceuticals' KRX-0401 (Perifosine) Data Selected for Oral Presentation at the 50th Annual Meeting of the American Society of Hematology
- Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2008 Financial Results on Tuesday, November 11, at 8:30 A.M. EST
- Keryx Biopharmaceuticals Notified that Nasdaq Has Extended Minimum Bid Price Rule Compliance Period
More News related to Downgrades
- Fort Dearborn Income Securities Inc. Reports Dividend and Long-Term Capital Gains Distribution
- F.N.B. Capital Corporation Provides Mezzanine Financing to Support Point Lookout Capital Partners in Acquiring Tri-Tech, Inc.
- Fitch Rates New York City's $308MM GOs 'AA-'; Outlook Stable
- Olympia Asset Management LTD Featured in Wall Street Letter
- Component Changes Made to Dow Jones Select Dividend Indexes
BofA downgrades Keryx Biopharmaceuticals (Nasdaq: KERX) from Buy to Neutral.
Keryx Biopharmaceuticals, Inc. (Keryx) is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of diseases, including diabetes and cancer.
Related Categories
DowngradesStocks Mentioned
+0.01Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
